



ACETADOTE
(acetylcysteine) Injection

CUMBERLAND PHARMACEUTICALS LAUNCHES ACETADOTE®

National sales force to make product available to hospitals

NASHVILLE, TENN. (June 4, 2004) – **Cumberland Pharmaceuticals Inc.** is pleased to announce the nationwide launch of Acetadote®, the first injectable drug to treat acetaminophen overdose in the United States.

Acetadote® (acetylcysteine) Injection, which received approval from the U.S. Food and Drug Administration (FDA) earlier this year, will be used in an emergency room setting to prevent or lessen potential liver damage resulting from acetaminophen overdose, the leading cause of drug toxicity in the United States. According to the American Association of Poison Control Centers, there are over 100,000 poisonings, 59,000 treatments in health facilities and 200 deaths each year due to overdoses of acetaminophen, a common ingredient in many over-the-counter painkillers and cough/cold preparations.

Cumberland has assembled a new team of institutional medical representatives to introduce Acetadote to hospitals and poison control centers around the country. Hospitals and other healthcare institutions interested in obtaining product supplies should contact their wholesalers. The product will be supported by a multifaceted educational campaign including peer reviewed clinical & pharmacy journal literature and advertising, mail communications, and exhibits at medical meetings & events. For more product information, visit www.acetadote.com.



“We have always believed Acetadote fills an important medical need and has the potential to save many lives,” said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. “The intense level of interest we have experienced since the product’s FDA approval has been gratifying, and we are excited to begin the process of making the product available to hospitals and patients across the nation.”

The FDA has granted Acetadote orphan drug status providing seven years of exclusivity from the date of approval. Orphan drugs are products used to treat conditions affecting fewer than 200,000 Americans each year.

Cumberland Pharmaceuticals Inc. is a Tennessee-based company formed to acquire rights to and actively market a portfolio of niche pharmaceuticals to specific physician specialties such as gastroenterology, critical care, emergency medicine and pulmonology. For more information, visit www.cumberlandpharma.com.